NAFLD

Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.

Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.

Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients

iBiopsy study shows promise in diagnosing severity of disease in patients

Transcriptome sequencing of patients with liver disease reveals gene expression changes that could help to track disease severity and progression

Owlstone study pinpoints limonene for early diagnosis of NASH and NAFLD